6,963 publications from this institution
Asthma is a serious health problem throughout the world. During the past two decades, many scientific advances have improved our understanding of asthma and ability to manage and control it effectively. However, recommendations for asthma care need to be adapted to local conditions, resources and services. Since it was formed in 1993, the Global Initiative for Asthma, a network of individuals, organisations and public health officials, has played a leading role in disseminating information about the care of patients with asthma based on a process of continuous review of published scientific investigations. A comprehensive workshop report entitled "A Global Strategy for Asthma Management and Prevention", first published in 1995, has been widely adopted, translated and reproduced, and forms the basis for many national guidelines. The 2006 report contains important new themes. First, it asserts that "it is reasonable to expect that in most patients with asthma, control of the disease can and should be achieved and maintained," and recommends a change in approach to asthma management, with asthma control, rather than asthma severity, being the focus of treatment decisions. The importance of the patient-care giver partnership and guided self-management, along with setting goals for treatment, are also emphasised.
The purpose of the study was to determine whether catecholamines modulate cholinergic neurotransmission in isolated human airway smooth muscle. Bronchial rings were suspended in organ baths for isometric measurement of tension, and contractions were induced by either electrical field stimulation (EFS) or exogenous acetylcholine (ACh). Isoproterenol, epinephrine, and norepinephrine in that order of potency produced concentration-dependent inhibition of comparable responses to EFS and ACh. However a potency difference of 100-fold for isoproterenol (IC50 = 4.80 X 10(-8) M for EFS and 3.70 X 10(-6) M for ACh) and 10-fold for both epinephrine and norepinephrine was observed for inhibition of responses to EFS compared with responses to ACh. The inhibitory effects of isoproterenol on responses to EFS were prevented by propranolol and ICI 118551 (a beta 2-antagonist) but not by betaxolol (a beta 1-antagonist). Tyramine had no effect on contractions elicited by EFS. These experiments demonstrate that beta-agonists inhibit cholinergic nerve-induced contractions of human bronchi more potently than contractions induced by exogenous ACh, suggesting modulation of cholinergic neurotransmission by prejunctional beta 2-receptors.
Journal Article Stenting of coronary arteries. Are we the sorcerer's apprentice? Get access P. W. SERRUYS, P. W. SERRUYS Thoraxcenter, Erasmus UniversityRotterdam, The Netherlands Address for correspondence: Patrick W. Serruys, Catheterisation Laboratory, Thoraxcenter, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR Rotterdan, The Netherlands. Search for other works by this author on: Oxford Academic PubMed Google Scholar K. J. BEATT, K. J. BEATT Thoraxcenter, Erasmus UniversityRotterdam, The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar W. J. VAN DER GIESSEN W. J. VAN DER GIESSEN Thoraxcenter, Erasmus UniversityRotterdam, The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar European Heart Journal, Volume 10, Issue 9, September 1989, Pages 774–782, https://doi.org/10.1093/oxfordjournals.eurheartj.a059570 Published: 01 September 1989 Article history Received: 13 June 1989 Accepted: 21 June 1989 Published: 01 September 1989
Background— Nonserial observations have shown this bioresorbable scaffold to have no signs of area reduction at 6 months and recovery of vasomotion at 1 year. Serial observations at 6 months and 2 years have to confirm the absence of late restenosis or unfavorable imaging outcomes. Methods and Results— The ABSORB trial is a multicenter single-arm trial assessing the safety and performance of an everolimus-eluting bioresorbable vascular scaffold. Forty-five patients underwent serial invasive imaging, such as quantitative coronary angiography, intravascular ultrasound, and optical coherence tomography at 6 and 24 months of follow-up. From 6 to 24 months, late luminal loss increased from 0.16±0.18 to 0.27±0.20 mm on quantitative coronary angiography, with an increase in neointima of 0.68±0.43 mm 2 on optical coherence tomography and 0.17±0.26 mm 2 on intravascular ultrasound. Struts still recognizable on optical coherence tomography at 2 years showed 99% of neointimal coverage with optical and ultrasonic signs of bioresorption accompanied by increase in mean scaffold area compared with baseline (0.54±1.09 mm 2 on intravascular ultrasound, P =0.003 and 0.77±1.33 m 2 on optical coherence tomography, P =0.016). Two-year major adverse cardiac event rate was 6.8% without any scaffold thrombosis. Conclusions— This serial analysis of the second generation of the everolimus-eluting bioresorbable vascular scaffold confirmed, at medium term, the safety and efficacy of the new device. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00856856.
